Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 684M P/E - EPS this Y 19.60% Ern Qtrly Grth -
Income -327.26M Forward P/E -2.01 EPS next Y 4.80% 50D Avg Chg -10.00%
Sales 95k PEG -1.72 EPS past 5Y - 200D Avg Chg -30.00%
Dividend N/A Price/Book 1.26 EPS next 5Y 1.00% 52W High Chg -73.00%
Recommedations 2.00 Quick Ratio 12.15 Shares Outstanding 170.72M 52W Low Chg 9.00%
Insider Own 22.22% ROA -26.84% Shares Float 116.93M Beta 0.80
Inst Own 72.96% ROE -55.51% Shares Shorted/Prior 31.36M/27.75M Price 4.69
Gross Margin - Profit Margin - Avg. Volume 2,616,766 Target Price 9.69
Oper. Margin 163,475.00% Earnings Date May 1 Volume 2,684,209 Change -2.09%
About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Allogene Therapeutics, Inc. News
04/26/24 Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
04/25/24 Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
04/24/24 Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
04/11/24 3 Meme Stocks to Sell and Replace With Meme Coins
04/09/24 Allogene Therapeutics Announces Q2 Investor Conference Participation
04/08/24 How Allogene (ALLO) Stock Stands Out in a Strong Industry
04/07/24 We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
03/16/24 Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript
03/15/24 Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss
03/15/24 Q4 2023 Allogene Therapeutics Inc Earnings Call
03/14/24 Allogene Therapeutics Inc (ALLO) Reports Q4 and Full Year 2023 Financials, Forecasts Cash ...
03/14/24 Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates
03/14/24 Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
03/13/24 Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology
03/12/24 Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease
03/12/24 Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
03/05/24 Allogene Therapeutics (ALLO)'s Technical Outlook is Bright After Key Golden Cross
03/05/24 Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
02/28/24 Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
02/16/24 Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
ALLO Chatroom

User Image Jizzle14 Posted - 4 hours ago

$ALLO added more today 2.73

User Image Thatguy2021 Posted - 10 hours ago

$ALLO This is going nowhere fast. GLTA

User Image ksheth1207 Posted - 1 day ago

$ALLO

User Image Jizzle14 Posted - 4 days ago

$ALLO DCA dwn at 2.79 today...brings me closer to $3. Phase 1 TRAVERSE trial, which may facilitate expanded use of Car Ts in solid tumors, is planned for a publication in Q2 '24. Safety algorithms have to be exact so good news.

User Image Thatguy2021 Posted - 4 days ago

$ALLO Someone should be sentenced to prison for allowing this to continue.

User Image nycmax2002 Posted - 4 days ago

$ALLO they did a full retrace.... Vicious because no catalysts

User Image AS1980 Posted - 4 days ago

$ALLO company is sick Stock is shit Shorts got rich here Arie does not give a fck

User Image Stock_Titan Posted - 4 days ago

$ALLO Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma https://www.stocktitan.net/news/ALLO/allogene-therapeutics-awarded-grant-from-the-california-institute-sth5rr23unnl.html

User Image Jizzle14 Posted - 5 days ago

$ALLO Looks like a good day to add to my position. ER report should be out within the next week or so. We expect the company to report earnings of -$0.39 per share, reflecting a year-over-year increase of 42.65%.

User Image major_tom Posted - 5 days ago

$BCRX $IBRX $ALLO $AUPH the biotech is always played by the big boys as the bitch of the sectors

User Image Jizzle14 Posted - 6 days ago

$ALLO do we bounce tomorrow or continue into the 2s? Adding if either way 😃

User Image BugHunti Posted - 6 days ago

$ALLO back under $2

User Image Diggit Posted - 6 days ago

$ALLO it's a biotech..no earnings until they release something significants it's just a rank bet with zero support

User Image IdiotBanker Posted - 6 days ago

$ALLO We are heading to some major volume resistance (right). Will it bounce or break through. We are currently at a 9 count downward move. If it breaks through we are heading to double bottom 2.27 or the orange trend line of .80. I Lean towards bounce. Probably re-enter later today or tomorrow. I should wait for a confirmation with a move above the 9ma (red line move down).

User Image BugHunti Posted - 6 days ago

$ALLO why going down here? where is the bottom?

User Image ozzy790 Posted - 1 week ago

$ALLO holding long on this one will pay, not tomorrow, but patience on this long term investment will pay back good money

User Image Thatguy2021 Posted - 1 week ago

$ALLO Who here is surprised by this sudden sell off. Total BS

User Image Daryl142 Posted - 1 week ago

$ALLO $6 be EOW! Wait, I said that a few months ago and I was wrong:(

User Image KnuckleSandwich Posted - 1 week ago

$ALLO

User Image BugHunti Posted - 1 week ago

$ALLO

User Image dojidad Posted - 1 week ago

$ALLO This is a chart from a post last month showing what to look for in a reversal. About 700 new people have joined our group since then, so I thought I would post it again. These were the signs of a reversal. There was a bearish engulfing candle which signaled trouble might be ahead. There was divergence, which means there was an uptrend and at the same time another indicator showed a downtrend (in this instance, the RSI). There was also declining volume and a rising price. Those are all indicators of a possible reversal, which happened. Once the 5-day EMA (green line) crossed below the 10-day SMA (yellow line), that was confirmation to sell. As long as this trades under the 5-day (green line), it is not a buy signal, IMO. This is a perfect example of how a reversal looks.

User Image Mr_JokeR Posted - 2 weeks ago

$ALLO painful.

User Image CaptObvious2014 Posted - 2 weeks ago

$ALLO 🎲 …..long. GL

User Image CaptObvious2014 Posted - 2 weeks ago

$ALLO Here we are. If 3.54 breaks…🥶

User Image AS1980 Posted - 2 weeks ago

$ALLO Arie we r tired man Move your fckn ass Do something, deliver anything, I don’t know, you r the man

User Image dojidad Posted - 2 weeks ago

@elbowcrooker Just an opinion, but as long as the 5-day EMA (green line) is under the 10-day SMA (yellow line), it mathematically can't have a sustainable uptrend. It's also under all the moving averages. I hope it reverses quickly for you! $ALLO

User Image Oversold_Gems Posted - 2 weeks ago

$ALLO

User Image elbowcrooker Posted - 2 weeks ago

$ALLO started a position here at 3.88 let us see where we go

User Image Mr_JokeR Posted - 2 weeks ago

$ALLO waiting for data to drop

User Image Stock_Titan Posted - 3 weeks ago

$ALLO Allogene Therapeutics Announces Q2 Investor Conference Participation https://www.stocktitan.net/news/ALLO/allogene-therapeutics-announces-q2-investor-conference-u1wha8tp39zc.html

Analyst Ratings
HC Wainwright & Co. Buy Mar 19, 24
RBC Capital Outperform Mar 15, 24
JP Morgan Overweight Feb 27, 24
HC Wainwright & Co. Buy Jan 19, 24
Guggenheim Neutral Jan 5, 24
JMP Securities Market Perform Jan 5, 24
Citigroup Buy Dec 8, 23
HC Wainwright & Co. Buy Nov 15, 23
JP Morgan Overweight Sep 25, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Mayo Stephen Director Director Aug 07 Sell 4.2855 10,000 42,855 25,328 08/09/23
Bhavnagri Veer General Counsel General Counsel Jan 17 Sell 7.04 3,000 21,120 580,677 01/18/23
WITTE OWEN N. Director Director Aug 11 Sell 16.88 15,000 253,200 218,271 08/15/22
Amado Rafael EVP of R&D and CMO EVP of R&D and CMO Aug 02 Sell 11.97 2,000 23,940 540,257 08/02/22
Amado Rafael EVP of R&D and CMO EVP of R&D and CMO Jun 21 Sell 11.18 2,000 22,360 544,257 06/22/22
Amado Rafael EVP of R&D and CMO EVP of R&D and CMO May 19 Sell 7.3993 11,500 85,092 546,257 05/19/22
Amado Rafael EVP of R&D and CMO EVP of R&D and CMO Mar 15 Sell 7.7090 5,169 39,848 320,119 03/17/22
Bhavnagri Veer General Counsel General Counsel Mar 15 Sell 7.6802 8,849 67,962 413,841 03/17/22
Chang David D President and CEO President and CEO Mar 15 Sell 7.6488 23,648 180,879 2,289,652 03/17/22
SCHMIDT ERIC THOMAS Chief Financial Offi.. Chief Financial Officer Mar 15 Sell 7.6337 11,469 87,551 100,546 03/17/22
MOORE ALISON Chief Technical Offi.. Chief Technical Officer Mar 15 Sell 7.6326 8,698 66,388 120,430 03/17/22
Kazam Joshua A Director Director Jan 12 Buy 12.60 15,000 189,000 258,885 01/14/22
Belldegrun Arie Director Director Jan 12 Buy 12.60 155,039 1,953,491 195,039 01/14/22
SCHMIDT ERIC THOMAS Chief Financial Offi.. Chief Financial Officer Jan 19 Sell 31.82 30,000 954,600 1,152,595 01/19/21
SCHMIDT ERIC THOMAS Chief Financial Offi.. Chief Financial Officer Nov 18 Sell 32.8 15,000 492,000 1,182,595 11/18/20
SCHMIDT ERIC THOMAS Chief Financial Offi.. Chief Financial Officer Oct 16 Sell 41.24 15,000 618,600 1,197,595 10/16/20
MOORE ALISON Chief Technical Offi.. Chief Technical Officer Oct 09 Option 2.27 35,264 80,049 147,879 10/09/20
MOORE ALISON Chief Technical Offi.. Chief Technical Officer Oct 09 Sell 41 44,574 1,827,534 108,370 10/09/20
MOORE ALISON Chief Technical Offi.. Chief Technical Officer Oct 08 Option 2.27 35,264 80,049 161,536 10/08/20
MOORE ALISON Chief Technical Offi.. Chief Technical Officer Oct 08 Sell 40 44,574 1,782,960 117,680 10/08/20
Bhavnagri Veer General Counsel General Counsel Oct 08 Option 2.27 10,000 22,700 363,902 10/08/20
Bhavnagri Veer General Counsel General Counsel Oct 08 Sell 40 10,000 400,000 353,902 10/08/20
SCHMIDT ERIC THOMAS Chief Financial Offi.. Chief Financial Officer Sep 22 Sell 35.92 15,000 538,800 1,212,595 09/22/20